Squamous Cell Carcinoma Secondary to BRAF Inhibitor Treatment for Metastatic Melanoma

0.75 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Desiree Ratner, MD

Desiree Ratner, MD
Professor of Clinical Dermatology
Director of Dermatology Surgery
Columbia University Medical Center
New York, NY

Desiree Ratner, MD, is Professor of Clinical Dermatology and Director of Dermatologic Surgery at Columbia University Medical Center, specializing in Mohs micrographic surgery, cutaneous oncology, and facial reconstruction. Dr. Ratner completed her medical training at Johns Hopkins University School of Medicine. She completed her internship in internal medicine at Beth Israel Hospital in Boston, followed by her dermatology residency at the University of Michigan Medical Center in Ann Arbor. She then fulfilled two years of fellowship training in Mohs micrographic surgery, reconstruction, and general dermatologic surgery with Dr. Donald Grande, first at New England Medical Center in Boston, MA, and then at the Lahey Clinic in Burlington, MA. After practicing in Baltimore and teaching in the Departments of Dermatology at Johns Hopkins and the University of Maryland affiliated Veterans Hospital, she returned to New York City and began full-time academic practice at Columbia in 1997.
Dr. Ratner has served on the Boards of Directors of the American College of Mohs Surgery, the International Transplant Skin Cancer Collaborative Group, and the Association of Academic Dermatologic Surgeons. She has served as Chair of the Sulzberger Institute of the American Academy of Dermatology and is currently Chair of the Procedural Dermatology section of the Association of Professors of Dermatology. She has been a co-editor of the Dermatologic Surgery Journal since 2007, and is currently an editorial board member for the Journal of the American Academy of Dermatology. She has authored or coauthored more than 80 publications and has given over 100 presentations at national and international meetings. She has been listed as one of the Castle Connolly Top Doctors since 2005, and as one of the New York Times' Best Doctors and America's Top Surgeons since 2009.

Patricia M. LoRusso, DO

Patricia M. LoRusso, DO
Director, Eisenberg Center for Translational Therapeutics
Karmanos Cancer Institute
Professor of Medicine
Wayne State Universtiy School of Medicine
Detroit, MI

Patricia LoRusso, DO, is a Professor of Oncology at Wayne State University, Division of Hematology/Oncology, and Faculty of the Karmanos Cancer Institute, Detroit, Michigan. Her primary interest is experimental therapeutics with a focus on phase I clinical research and novel trial designs. She currently directs one of only 14 National Cancer Institute (NCI) U01-funded phase I sites in North America. Dr. LoRusso serves as co-chair of the NCI Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee. She has also served on the education and scientific committees of the American Society of Clinical Oncology, the scientific committee of the American Association for Cancer Research, and as a parent member of the NCI's Quick Trials Clinical Subcommittee. She has served either ad hoc or as an appointed member on multiple study sections, including Subcommittee D of the Program Projects Grants, and Small Business Innovation Research and Department of Defense study sections. 
Dr. LoRusso has reviewed for Komen Promise grants, numerous SPORE and P01 study sections, and translational research grants. She served four years as a faculty member of the Methods in Clinical Cancer Research Workshop in Flims, Switzerland, and six years at the Methods in Clinical Cancer Research Workshop in Vail, Colorado. In 1999, Dr. LoRusso was awarded the Hero of Breast Cancer award and in 2004 the Bennett J. Cohen Educational Leadership Award for Medical Research. She received the Marygrove College Distinguished Alumni Award and was named one of Crain's Detroit Business Health Care Heroes. She was also recognized with the 2008 Michaele C. Christian Oncology Drug Development Award and Lectureship from NCI CTEP.
1. Incorporate findings from molecular tumor analyses into treatment selection for patients with melanoma and nonmelanoma skin cancer
2. Evaluate new efficacy and safety evidence on cytotoxic, immune-based, and molecularly targeted treatment options in the 1st-line and 2nd-line settings to determine optimal treatment across the natural history of melanoma